Background: GABAergic inhibition is essential for normal cortical function as it serves the purpose of proper excitation/inhibition (E/I) balance in many circuits. In contrast, inappropriate interneuron signaling leads to E/I imbalance, reduced gamma oscillations in EEG measurements and has serious behavioural consequences. Among the heterogeneous group of GABAergic cells, fast-spiking, parvalbumin positive interneurons (FS-PV+) play a key role in the generation and maintenance of gamma oscillations. E/I imbalance due to interneuron dysfunction has been implicated in the pathophysiology of various psychiatric disorders. Cognitive impairment has been associated with altered gamma oscillation in schizophrenia and there is accumulating evidence for involvement of FS-PV+ interneuron deficit in the disease. Hypofunction of FS-PV+ neurons leads to disinhibition of pyramidal cells which cause network desynchronization. Therefore, it is hypothesized that activation of these neurons could restore high-frequency oscillations and consequently improve cognitive functions. However selective modulation of different interneuron types is still challenging due to limited number of known cell type specific targets. Methods: A possible starting point for the treatment could be pharmacological activation of voltage gated sodium channels (Nav) which have a pivotal role in action potential initiation. Of the four subtypes of Nav channels expressed in the CNS Nav 1.1 comprises the majority of the sodium current in FS-PV+ but not in pyramidal neurons. Based on this we looked for selective Nav 1.1 activators and found a recently published promising compound (Compound 3a, see Crestey et al, 2015) which has been shown to increase the electrical activity of FS-PV+ interneurons in the CA1 area of the hippocampus. However, the dysfunction in information processing found in schizophrenic patients is not only restricted to the hippocampus and high-order association cortices but also influences the sensory cortex. Thus, our aim was to explore the effect of the selective Nav 1.1 positive modulator Compound 3a on FS interneurons in the mouse somatosensory cortex. We performed whole-cell patch clamp recordings from mouse cortical brain slices and recorded the electrical activity of single FS cells before and after the drug application. Results: Surprisingly the excitatory effect of the compound 3a could only partly be confirmed in the way that positive modulation of Nav1.1 in terms of action potential number and threshold only takes place under particular conditions, i.e. at physiological temperature and under specific ion compositions of the recording solutions Discussion: The discrepancy of our results from published data might be attributed to the different experimental conditions such as recording temperature and ionic composition of solutions and highlight the importance of selecting near physiological conditions during brain slice patch clamp experiments.
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Background: Schizotypy traits range from odd behaviors to symptoms that resemble full schizophrenia, although less severe. Previous studies associated different degrees of positive and negative schizotypal traits to variations in the persons' cognitive profiles while others related them to the risk to develop psychosis. We hypothesize that similar pattern of positive and negative schyzoypy traits characterize individuals at risk of psychosis and patients meeting the criteria for recent onset psychosis, although with different degrees of severity. Also, both should differ from depressed patients. Moreover, specific combinations of schizotypy traits and neurocognitive alterations should be associated to the different psychopathological profiles. The final goal of the study is to identify candidate predictors of risk of psychosis that will be used as features in next machine learning analyses. Methods: The present is a multi-centric study that was conducted as part of the project titled 'Personalised Prognostic Tools for Early Psychosis Management' (PRONIA). 115 participants at high-risk for psychosis (CHR), 114 recent onset psychosis (ROP), 123 recent onset depression (ROD) and 252 healthy controls (HC) took part in the study. All were aged between 15 and 40 years. The participants filled the Wisconsin Schizotypy questionnaire, measuring positive (Magical Ideation Scale -MIS; Perceptual Aberration Scale -PAS) and negative schizotypy traits (Social Anhedonia Scale -SAnS; Physical Anhedonia Scale -PAnS). Moreover, they were administered the PRONIA Cognitive Battery (PCB), comprising measures of visuo-spatial dexterity and memory (Rey Figure, copy and delayed drawing), short-term memory (Digit Span -DS), Verbal Learning, Verbal Fluency, Attention (Continuous Performance Test -CPT, Digit Symbol Substitution Test -DSST), Emotions' Recognition, General Intelligence (WAIS Vocabulary, Matrix Reasoning).
Results:
We run i) a Multivariate Analysis of Covariance with 'WSS subscales' as dependent variable; 'Group' as between subject factor; 'Age' and 'Gender' as covariates; ii) a Multinomial logistic regression with 'Group' as dependent variable; HC 'Group' as reference parameter; 'WSS subscales' and scores at the PCB's tests as predictors; 'Age' and 'Gender' as covariates. ROP and CHR reported both positive and negative schizotypy traits, although only the negative symptoms involving social aspects were clearly evident in CHR. Also, ROP and CHR differed for the positive symptoms, as they were present but at a lower level in CHR than in ROP. ROD instead scored high at the negative symptoms. Interestingly, ROP, CHR and ROD did not differ between each other for the negative symptoms, probably reflecting the effect of the psychopathology on the patients' general motivation to life. The regressions analysis highlighted different patterns of associations of WSS and neurocognitive scores with the clinical status. In particular, the scores at the MIS, PAS and SanS combined with the Rey Figure ( delayed drawing), predicted that the participants were CHR; the MIS, PAS and SAnS with measures of attention (CPT, DSST) predicted that the participant were ROP; the PAS; SAnS and short-term memory (DS) predicted to being ROD. Discussion: Coherently with the hypotheses, different schizotypy traits or grade of severity characterized patients with distinct psychopathology profiles. Also, the association of WSS subscales with the cognitive measures differentiated between groups, with visuo-spatial long-term memory being associated to CHR, measures of attention relating to ROP and verbal short term memory relating to ROD. This makes these measures good candidates for the upcoming machine learning analyses. Background: The aim of this study was to explore the prognosis and predictors of outcomes in schizophrenia in a birth cohort sample followed since mid-pregnancy until the age of 45 years. Methods: The sample included subjects with schizophrenia (n=29-161, depending on the analyzed topic) from the Northern Finland Birth Cohort 1966. Outcomes and their predictors were analyzed by utilizing national registers, questionnaires and personal examinations made on several time points (e.g. during pregnancy, at age 1 year, 34-and 43-years). Functioning, amount of psychiatric symptoms, utilization of treatments, physical illnesses and mortality, and cognition were used as measures of outcomes. Several plausible factors associating to outcomes were studied, e.g. gender, family history of psychosis, development and childhood related factors, school performance, and illness related factors around the onset of psychosis, brain morphology and cognitive functioning, and lifetime antipsychotic medication. Results: Around the age of 34-years recovery was possible though quite uncommon (3.4%), some persons achieved symptomatic remission (21%), and many were on disability pension (54%). Around the age of 43-45 years only 11.2% were employed, and 19% were in remission. Earlier age of illness onset, longer duration of untreated psychosis, suicidal ideation and poorer functioning around illness onset, brain morphological changes and poorer cognition, and higher lifetime doses of antipsychotics associated to poor outcomes. Cognition did not markedly decline from 34 to 43 years of age, but poorer premorbid school performance and higher lifetime doses of antipsychotics predicted more decline of cognition. For some cases, the cumulative amount of used antipsychotics was extensive. Somatic comorbidities were common, and mortality high. Background: Social cognitive dysfunction is common in patients with schizophrenia and is associated with marked and persistent functional disability. Facial emotion recognition is a core aspect of social cognition and has been consistently demonstrated to be impaired in this population. However, it remains unclear whether these deficits are unique to patients with schizophrenia. We compared the severity of facial emotion recognition deficits in patients with both sub-and full-threshold psychotic symptoms to those observed across a range of psychiatric, neurological and developmental disorders in order to determine to what extent this represents a disorder-specific or transdiagnostic aspect of cognitive dysfunction. Methods: We conducted an electronic database search in order to identify published, peer-reviewed meta-analyses that compared facial emotion recognition task performance between individuals meeting clinical criteria for a psychiatric, neurological or developmental condition against healthy controls. Facial emotion recognition standardized mean difference effect size estimates (Cohen's d or Hedges' g) were required to have been derived from tasks in which participants had to identify, label or match images of faces consisting of all or any combination of the six basic emotions (happiness, sadness, anger, fear, surprise or disgust). Where possible, a 'total' score was used, comprising performance across multiple emotions. Effect size estimates must have been derived from two or more independent studies in order for the meta-analysis to be included. Where there were multiple publications for a given medical condition that met our inclusion criteria, we included the most recently published paper. Results: We identified 19 meta-analyses eligible for inclusion that examined performance across relevant tasks among 24 different clinical populations. Though the effect sizes are not directly comparable across clinical conditions (due to methodological differences between studies and in meta-analytic procedures), they demonstrate consistent and statistically significant deficits in facial emotion recognition across almost all of the clinical groups included in this review. Effect size estimates indicated that deficits among patients with schizophrenia were among the largest and most robust. Deficits were also evident even among those individuals with sub-threshold psychotic symptoms who met clinical criteria for being at ultra-high risk of developing a psychotic disorder. Discussion: Facial emotion recognition deficits are a transdiagnostic issue, potentially serving as a biomarker of neurological abnormality. However, these impairments appear to be particularly severe and debilitating among people with schizophrenia. There are currently no recognized treatments for these deficits. This in part is due to a lack of outcome measures suitable for use in clinical trials. Improved characterization and operationalization of social cognition and other 'hot' cognitive processes are necessary to facilitate and advance treatment efforts, both in schizophrenia and across other clinical groups. We are currently in the process of developing and acquiring normative data for a series of computerized tasks which can be used to assess these domains. This includes new variants of established tests which have been used to assess facial emotion recognition, as well as novel tasks to detect emotional biases and assess responses to socially-relevant information. These tasks will help to facilitate further research into these complex social processes and potentially assist in the development of interventions for those patients that are adversely affected.
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